| Apixaban metabolism and pharmacokinetics after oral administration to humans N Raghavan, CE Frost, Z Yu, K He, H Zhang, WG Humphreys, D Pinto, ... Drug metabolism and disposition 37 (1), 74-81, 2009 | 793 | 2009 |
| Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions BW Ogilvie, D Zhang, W Li, AD Rodrigues, AE Gipson, J Holsapple, ... Drug Metabolism and Disposition 34 (1), 191-197, 2006 | 381 | 2006 |
| Preclinical experimental models of drug metabolism and disposition in drug discovery and development D Zhang, G Luo, X Ding, C Lu Acta Pharmaceutica Sinica B 2 (6), 549-561, 2012 | 358 | 2012 |
| In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation D Zhang, TJ Chando, DW Everett, CJ Patten, SS Dehal, WG Humphreys Drug Metabolism and Disposition 33 (11), 1729-1739, 2005 | 325 | 2005 |
| Mass defect filter technique and its applications to drug metabolite identification by high‐resolution mass spectrometry H Zhang, D Zhang, K Ray, M Zhu Journal of mass spectrometry 44 (7), 999-1016, 2009 | 320 | 2009 |
| In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies L Wang, D Zhang, N Raghavan, M Yao, L Ma, CA Frost, BD Maxwell, ... Drug Metabolism and Disposition 38 (3), 448-458, 2010 | 306 | 2010 |
| Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end‐stage renal disease on hemodialysis X Wang, G Tirucherai, TC Marbury, J Wang, M Chang, D Zhang, Y Song, ... The journal of clinical Pharmacology 56 (5), 628-636, 2016 | 297 | 2016 |
| Detection and characterization of metabolites in biological matrices using mass defect filtering of liquid chromatography/high resolution mass spectrometry data M Zhu, L Ma, D Zhang, K Ray, W Zhao, WG Humphreys, G Skiles, ... Drug metabolism and disposition 34 (10), 1722-1733, 2006 | 264 | 2006 |
| Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor PC Wong, DJP Pinto, D Zhang Journal of thrombosis and thrombolysis 31, 478-492, 2011 | 238 | 2011 |
| A software filter to remove interference ions from drug metabolites in accurate mass liquid chromatography/mass spectrometric analyses H Zhang, D Zhang, K Ray Journal of Mass Spectrometry 38 (10), 1110-1112, 2003 | 203 | 2003 |
| Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor X a inhibitor CE Frost, W Byon, Y Song, J Wang, AE Schuster, RA Boyd, D Zhang, Z Yu, ... British journal of clinical pharmacology 79 (5), 838-846, 2015 | 192 | 2015 |
| Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects X Wang, S Mondal, J Wang, G Tirucherai, D Zhang, RA Boyd, C Frost American Journal of Cardiovascular Drugs 14, 147-154, 2014 | 186 | 2014 |
| Targeted drug delivery through the traceless release of tertiary and heteroaryl amines from antibody–drug conjugates LR Staben, SG Koenig, SM Lehar, R Vandlen, D Zhang, J Chuh, SF Yu, ... Nature chemistry 8 (12), 1112-1119, 2016 | 138 | 2016 |
| Phase I and phase II enzymes produced by Cunninghamella elegans for the metabolism of xenobiotics D Zhang, Y Yang, JEA Leakey, CE Cerniglia FEMS microbiology letters 138 (2‐3), 221-226, 1996 | 138 | 1996 |
| A method for the large scale isolation of high transformation efficiency fungal genomic DNA D Zhang, Y Yang, LA Castlebury, CE Cerniglia FEMS microbiology letters 145 (2), 261-265, 1996 | 137 | 1996 |
| Characterization of efflux transporters involved in distribution and disposition of apixaban D Zhang, K He, JJ Herbst, J Kolb, W Shou, L Wang, PV Balimane, YH Han, ... Drug Metabolism and Disposition 41 (4), 827-835, 2013 | 134 | 2013 |
| Decoupling stability and release in disulfide bonds with antibody-small molecule conjugates GD Rosario Chemical Science 8 (1), 366-370, 2017 | 128 | 2017 |
| Cathepsin B is dispensable for cellular processing of cathepsin B-cleavable antibody–drug conjugates NG Caculitan, J dela Cruz Chuh, Y Ma, D Zhang, KR Kozak, Y Liu, ... Cancer research 77 (24), 7027-7037, 2017 | 124 | 2017 |
| Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans D Zhang, K He, N Raghavan, L Wang, J Mitroka, BD Maxwell, RM Knabb, ... Drug metabolism and disposition 37 (8), 1738-1748, 2009 | 122 | 2009 |
| Effect of rifampin on the pharmacokinetics of apixaban, an oral direct inhibitor of factor Xa B Vakkalagadda, C Frost, W Byon, RA Boyd, J Wang, D Zhang, Z Yu, ... American Journal of Cardiovascular Drugs 16, 119-127, 2016 | 119 | 2016 |
